Menu Search
Equities

EyePoint Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PV3B:FRA

EyePoint Inc

Actions
  • Price (EUR)10.69
  • Today's Change0.625 / 6.21%
  • Shares traded200.00
  • 1 Year change+43.49%
  • Beta1.8050
Data delayed at least 15 minutes, as of Feb 06 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

  • Revenue in USD (TTM)42.34m
  • Net income in USD-205.75m
  • Incorporated2008
  • Employees165.00
  • Location
    EyePoint Inc480 Pleasant Street, Suite C400WATERTOWN 02472United StatesUSA
  • Phone+1 (617) 926-5000
  • Fax+1 (617) 926-5050
  • Websitehttps://eyepoint.bio/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.